Tarsus Pharmaceuticals, Inc. (TARS) Tops Q4 EPS by 17c

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) reported Q4 EPS of ($0.60), $0.17 better than the analyst estimate of ($0.77). Revenue for the quarter came in at $66.41 million versus the consensus estimate of $57.53 million.

For earnings history and earnings-related data on Tarsus Pharmaceuticals, Inc. (TARS) click here.

You May Also Be Interested In

• Gulfport Energy and Mobility Global to join S&P SmallCap 600
• Matinas BioPharma gets NYSE American compliance notice
• Uranium Royalty Corp. sets shareholder vote on $1.14B Sweetwater deal